Soto-Cerrato V - Search Results

1

Targeting Autophagy for Cancer Treatment and Tumor Chemosensitization.

Pérez-Hernández M, Arias A, Martínez-García D, Pérez-Tomás R, Quesada R, Soto-Cerrato V. Pérez-Hernández M, et al. Cancers (Basel). 2019 Oct 19;11(10):1599. doi: 10.3390/cancers11101599. Cancers (Basel). 2019. PMID: 31635099 Free PMC article. Review.

2

The prodigiosins, proapoptotic drugs with anticancer properties.

Pérez-Tomás R, Montaner B, Llagostera E, Soto-Cerrato V. Pérez-Tomás R, et al. Biochem Pharmacol. 2003 Oct 15;66(8):1447-52. doi: 10.1016/s0006-2952(03)00496-9. Biochem Pharmacol. 2003. PMID: 14555220 Review.

3

Prodigiosin induces apoptosis by acting on mitochondria in human lung cancer cells.

Llagostera E, Soto-Cerrato V, Montaner B, Pérez-Tomás R. Llagostera E, et al. Ann N Y Acad Sci. 2003 Dec;1010:178-81. doi: 10.1196/annals.1299.030. Ann N Y Acad Sci. 2003. PMID: 15033716

4

Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin.

Soto-Cerrato V, Llagostera E, Montaner B, Scheffer GL, Perez-Tomas R. Soto-Cerrato V, et al. Biochem Pharmacol. 2004 Oct 1;68(7):1345-52. doi: 10.1016/j.bcp.2004.05.056. Biochem Pharmacol. 2004. PMID: 15345324

5

High cytotoxic sensitivity of the human small cell lung doxorubicin-resistant carcinoma (GLC4/ADR) cell line to prodigiosin through apoptosis activation.

Llagostera E, Soto-Cerrato V, Joshi R, Montaner B, Gimenez-Bonafé P, Pérez-Tomás R. Llagostera E, et al. Anticancer Drugs. 2005 Apr;16(4):393-9. doi: 10.1097/00001813-200504000-00005. Anticancer Drugs. 2005. PMID: 15746575

6

Cell cycle arrest and proapoptotic effects of the anticancer cyclodepsipeptide serratamolide (AT514) are independent of p53 status in breast cancer cells.

Soto-Cerrato V, Montaner B, Martinell M, Vilaseca M, Giralt E, Pérez-Tomás R. Soto-Cerrato V, et al. Biochem Pharmacol. 2005 Dec 19;71(1-2):32-41. doi: 10.1016/j.bcp.2005.10.020. Epub 2005 Nov 18. Biochem Pharmacol. 2005. PMID: 16298346

7

Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7 MR) cell line.

Monge M, Vilaseca M, Soto-Cerrato V, Montaner B, Giralt E, Pérez-Tomás R. Monge M, et al. Invest New Drugs. 2007 Feb;25(1):21-9. doi: 10.1007/s10637-006-7774-8. Invest New Drugs. 2007. PMID: 16633713

8

Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3beta activity in human breast cancer cells.

Soto-Cerrato V, Viñals F, Lambert JR, Kelly JA, Pérez-Tomás R. Soto-Cerrato V, et al. Mol Cancer Ther. 2007 Jan;6(1):362-9. doi: 10.1158/1535-7163.MCT-06-0266. Mol Cancer Ther. 2007. PMID: 17237295

9

Mechanisms of prodigiosin cytotoxicity in human neuroblastoma cell lines.

Francisco R, Pérez-Tomás R, Gimènez-Bonafé P, Soto-Cerrato V, Giménez-Xavier P, Ambrosio S. Francisco R, et al. Eur J Pharmacol. 2007 Oct 31;572(2-3):111-9. doi: 10.1016/j.ejphar.2007.06.054. Epub 2007 Jul 4. Eur J Pharmacol. 2007. PMID: 17678643

10

The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway.

Soto-Cerrato V, Viñals F, Lambert JR, Pérez-Tomás R. Soto-Cerrato V, et al. Biochem Pharmacol. 2007 Nov 1;74(9):1340-9. doi: 10.1016/j.bcp.2007.07.016. Epub 2007 Jul 18. Biochem Pharmacol. 2007. PMID: 17765876

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters